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Abstract
We estimated the effectiveness of four monovalent pandemic influenza A (H1N1) vaccines (three unadjuvanted inactivated,
one live attenuated) available in the U.S. during the pandemic. Patients with acute respiratory illness presenting to inpatient
and outpatient facilities affiliated with four collaborating institutions were prospectively recruited, consented, and tested for
influenza. Analyses were restricted to October 2009 through April 2010, when pandemic vaccine was available. Patients
testing positive for pandemic influenza by real-time RT-PCR were cases; those testing negative were controls. Vaccine
effectiveness was estimated in logistic regression models adjusted for study community, patient age, timing of illness,
insurance status, enrollment site, and presence of high-risk medical conditions. Pandemic virus was detected in 1,011 (15%)
of 6,757 enrolled patients. Fifteen (1%) of 1,011 influenza positive cases and 1,042 (18%) of 5,746 test-negative controls had
record-verified pandemic vaccination .14 days prior to illness onset. Adjusted effectiveness (95% confidence interval) for
pandemic vaccines combined was 56% (23%, 75%). Adjusted effectiveness for inactivated vaccines alone (79% of total) was
62% (25%, 81%) overall and 32% (292%, 76%), 89% (15%, 99%), and 26% (2231%, 66%) in those aged 0.5 to 9, 10 to 49,
and 50+ years, respectively. Effectiveness for the live attenuated vaccine in those aged 2 to 49 years was only demonstrated
if vaccination .7 rather than .14 days prior to illness onset was considered (61%: 12%, 82%). Inactivated non-adjuvanted
pandemic vaccines offered significant protection against confirmed pandemic influenza-associated medical care visits in
young adults.
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Introduction
In April 2009, human infections with a novel influenza A
(H1N1) virus were first detected in the US [1], with declaration of
a global pandemic by June 2009. By February 2010, 30 different
monovalent pandemic vaccines were licensed world-wide [2],
including four distributed in the US, which were analogous to
previously licensed seasonal influenza vaccines. The US inactivat-
ed vaccines licensed were non-adjuvanted and differed from those
licensed in Europe and Canada, where adjuvanted vaccines
predominated. A single dose of the inactivated US vaccines
generally elicited antibody responses associated with protection in
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vaccinees aged 10 years and older; however, a second dose was
required to achieve seroprotection among a high proportion of
young children [2,3].
Pandemic vaccines became available in the US by October
2009. Target groups for limited initial doses included health care
workers, pregnant women, close contacts of children aged ,6
months, all persons aged 6 months to 24 years, and persons 25
through 64 years with high-risk medical conditions [4]. By mid to
late December, vaccine was available for all, and about 125
million doses were eventually distributed.
We assessed the effectiveness of pandemic vaccines against
laboratory confirmed pandemic influenza associated health care
visits in four US communities through the Centers for Disease
Control and Prevention’s (CDC) Influenza Vaccine Effectiveness
(Flu-VE) Network.
Methods
Subject enrollment
We enrolled persons seeking care for acute respiratory illness at
medical facilities affiliated with the Marshfield Clinic and St.
Joseph’s Hospital, Marshfield, WI; the University of Michigan
Health System, Ann Arbor, MI and Henry Ford Health System,
Detroit, MI; the University of Rochester (Strong Memorial and
Rochester General Hospitals), NY; and Vanderbilt University,
Summit, St. Thomas and Baptist Hospitals, Nashville, TN.
Patients were prospectively enrolled from 9/1/2009 through 5/
31/2010. Analyses included subjects aged $6 months who were
enrolled at least 7 days after the first pandemic H1N1 vaccination
in an enrolled patient through 7 days following the last pandemic
influenza diagnosis in each study site: 10/06/09–12/21/09 (NY),
10/08/09–3/19/10 (WI), 10/09/09–4/9/10 (TN), and 10/23/
09–4/26/10 (MI).
The source populations included community-dwelling residents
in Marshfield, seen in primary care clinics or hospitals affiliated
with Marshfield Clinic; patients receiving care at selected
University of Michigan Health System or Henry Ford Health
System outpatient clinics or their affiliated hospitals; residents of
Monroe County (Rochester), NY admitted to two area hospitals or
emergency departments, or seen at 1 adult and 3 children’s
outpatient clinics; and residents of Davidson (Nashville) and
surrounding counties admitted to four area hospitals, two
associated emergency departments, or seen at 1 adult and 1
children’s outpatient clinics. Patients presenting with acute
respiratory illness were recruited by trained personnel 2–6 days
per week, depending on location and staffing, and were identified
by screening procedures (review of electronic records or other lists
of admission diagnoses or symptoms).
Potentially eligible patients (or parents/guardians) were ap-
proached by trained staff to assess eligibility and obtain informed
consent. Each consented participant (or parent/guardian) com-
pleted an interview to ascertain symptoms and date of symptom
onset. Age, sex, self-reported race, insurance status, and history of
chronic medical conditions were ascertained from interview and/
or medical record review. Persons were defined as high risk if they
had documented medical conditions that increase the risk of
influenza complications, as defined by the Advisory Committee on
Immunization Practices [5]. Weight and height were not
uniformly collected; thus, obesity data were not available.
In three communities, receipt of pandemic and seasonal 2009–
10 influenza vaccines was ascertained by patient or parental report
and confirmed by medical record review and/or State vaccine
registries. In Wisconsin, vaccine receipt was confirmed by a
vaccine registry which captures 95% of all influenza (including
pandemic) vaccinations in that population [6,7].
Study procedures, informed consent documents and data
collection forms were reviewed and approved by Institutional
Review Boards of Marshfield Clinic, University of Michigan,
University of Rochester, and Vanderbilt University, St Thomas
and Baptist Hospitals (Sterling), and Summit Hospital (Western),
and the Centers for Disease Control and Protection. Written
consent/assent was obtained from all study participants and/or
their parents/guardians.
Laboratory methods
Respiratory specimen swabs collected from each enrolled
patient were tested at the study sites using CDC’s real-time RT-
PCR (rRT-PCR) protocol for detection and characterization of
influenza viruses using dual-labeled probe (TaqmanH) chemistry.
CDC provided primers, probes, and control materials, and a
proficiency testing panel was completed by each site. A sample of
rRT-PCR-positive specimens was cultured using MDCK cells and
a subset of viral isolates was antigenically characterized by CDC
using a hemagglutination inhibition assay with a panel of standard
reference viruses and the corresponding post-infection ferret
antisera [8].
Vaccine effectiveness estimates
The primary outcome was medically attended acute respiratory
illness with rRT-PCR confirmed pandemic influenza virus
detected. The primary exposure was receipt of a single pandemic
vaccine .14 days before illness onset. Vaccine effectiveness was
estimated as 100%6(12adjusted odds ratio) using logistic
regression models. The primary model included all pre-specified
potential confounders. Day of symptom onset was modeled as days
since pandemic vaccine availability using linear tail-restricted
cubic spline functions, with four knots at 5%, 35%, 65% and 95%
quantiles. Spline functions can describe continuous data well,
while economizing on the degrees of freedom used [9]. Other pre-
specified potential confounders included: age, study community,
insurance status, enrollment site, and presence of high-risk medical
conditions. Stratified analyses were performed by age category: 6
months to ,10 years, because one dose of vaccine was considered
partial vaccination for this group; 10–49 years, as a single dose
resulted in high levels of seroprotection in this group [2,3]; and 50
years and older, a group with relatively low pandemic influenza
attack rates. We also examined effectiveness of inactivated
pandemic and live attenuated vaccines separately. We did not
perform analyses by study community or enrollment site because
of limited sample size. Secondary analyses used a 7- rather than
14-day period between vaccination and illness onset to define
immunization, since seroprotective levels are often evident within
the first week following vaccination [10,11]. We also evaluated the
effectiveness of the 2009–2010 seasonal vaccines for prevention of
pandemic illness, controlling for receipt of pandemic vaccine.
Finally, because of strong confounding by age and illness onset
date relative to vaccine availability, an alternate analytic model
was developed, which adjusted for age and time using categories,
with linear adjustment within categories rather than spline
functions (supplementary Table S1).
Analyses were conducted using R 2.10.1 (r-project.org) for
descriptive statistics and the primary model and SAS 9.1 software
(SAS Institute, Cary, NC) for the alternate analytic model. A 95%
confidence interval (CI) was calculated for each estimate; if this
interval excluded 0%, the estimate was considered statistically
significant. Data are expressed as median (interquartile range
[IQR]) or frequency (percentage). Comparisons between cases and
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controls, and between vaccinated and unvaccinated patients used
Wilcoxon rank-sum test for continuous variables and chi-square
test for categorical variables.
Results
Of 10,004 patients with medically attended acute respiratory
illness enrolled from September 2009 through May 2010, 6,757
(68%) patients were included in case-control analyses. Exclusions
were for inconclusive laboratory results (n = 33), age ,6 months
(n = 321), enrollment before pandemic vaccine availability
(n = 1320) or following the last pandemic influenza diagnosis
(n = 1442), and non-verified vaccination status (n = 131).
Of 6,757 study patients, 1,011 (15%) tested positive for
pandemic influenza virus. CDC further characterized all 70
cultured and submitted viruses as A/California/07/2009-like
(H1N1). Pandemic virus circulation peaked at study sites just as
vaccine became available. During October, ,1% and 3% of
enrolled controls had been vaccinated .14 and .7 days before
illness onset, respectively. Vaccination levels rose quickly and
approached 27% in controls overall, remaining stable from
January through April 2010 (Figure 1).
The distribution of cases and controls differed by study
community (Table 1) in part due to timing of the pandemic, with
the last pandemic virus detected in December 2009 in Rochester
compared with March or April 2010 for the other 3 communities.
In addition to the strong association between case status and
calendar time (Figure 1), influenza positive and negative patients
differed in other ways (Table 1). Compared with controls, cases
were younger (median age 13 vs. 29 years), and less likely to be
Black (14% vs. 20%), to have a high-risk medical condition (32%
vs. 46%), or to be vaccinated. Cases were more likely to have
private insurance (71% vs. 60%) and be enrolled at an outpatient
setting (79% vs. 58%). Influenza positive cases also had shorter
symptom duration at presentation (63% vs. 44% with symptoms
,3 days).
Of the 1057 vaccinated patients, 21% received live attenuated
vaccine and 79% received one of three inactivated vaccines,
including sanofi-pasteur (48%), Novartis (22%), CSL (6%), and
manufacturer unknown (4%). In addition to the strong association
between vaccination and time (Figure 1), vaccinated patients were
younger than unvaccinated patients (median 11 vs. 27 years); less
likely to be Black (10% vs. 20%); and more likely to be insured,
enrolled in outpatient settings, and to have a longer symptom
duration prior to presentation (42% vs. 47% with symptoms ,3
days) (Table 2). Few vaccinees tested positive for pandemic
influenza (1% vs. 17% for unvaccinated patients).
Overall vaccine effectiveness was 56% (95% CI, 23%–75%)
adjusting for study community, date of illness onset, age, insurance
status, enrollment site, and presence of high-risk medical conditions
(Table 3). Controlling for race (missing in 177 patients) yielded
identical results. The crude vaccine effectiveness estimate of 93%
(based on the proportion of vaccinated case and controls) was biased
because pandemic influenza cases were skewed to the earlier time
when overall vaccination levels were low (Figure 1); adjusting for
calendar time was essential for all analyses. Given the strong temporal
trends with low numbers of cases during the period of greatest vaccine
availability, power for any stratified analyses was limited. None of the
age-specific adjusted analyses indicated significant vaccine effective-
ness. Too few children aged,10 years received two doses of vaccine
to estimate effectiveness separately for this group.
Overall results were similar when a 7-day interval defined
immunization (Table 4). Significant vaccine effectiveness was
demonstrated overall (58%, 95% CI, 32%–74%) and for those
aged 10 to 49 years (59%, 95% CI, 15%–80%). Results using an
alternate model to control for age and for timing of illness yielded
similar results (supplemental Table S1). In contrast to pandemic
vaccine, receipt of seasonal vaccine did not reduce medically
attended visits associated with pandemic virus infection (vaccine
effectiveness 11% (95% CI 29%–27%) (supplemental Table S1).
Adjusted effectiveness of inactivated vaccines (79% of total) was
62% (95% CI, 25%–81%) overall and 89% (95% CI, 15%–99%)
among those aged 10 to 49 years. Using a 7- rather than 14-day
interval, estimates were modestly lower but significant overall
(59%, 95% CI, 26%–77%) and for those aged 10 to 49 years
(77%, 95% CI, 25%–93%).
Figure 1. Number of influenza-positive cases and influenza-negative controls enrolled in the Flu-VE study by month of illness
onset, October 2009 through April 2010, and percent vaccinated greater .14 days prior to illness onset. (Vaccination rates were ,1%
in October).
doi:10.1371/journal.pone.0023085.g001
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Live attenuated vaccine was evaluated among those aged 2 to
49 years, for whom the vaccine is licensed. Significant effectiveness
was not demonstrated in the primary analysis. Using a 7-day
interval, vaccine effectiveness was estimated as 61% (95% CI,
12%–82%) among those aged 2–49 years and 82% (95% CI,
14%–96%) among those aged 2 to 9 years (Tables 3 and 4).
Discussion
We prospectively identified .1000 patients with pandemic
influenza-associated illness resulting in a medical encounter
following availability of US pandemic vaccines. Pandemic vaccines
offered significant overall protection against medically attended
influenza illnesses. These findings in four geographically and
economically diverse communities are relevant to the entire US.
The timing of pandemic virus-associated illness in the combined
study communities reflected that of the rest of the US, with a first
peak in June–July 2009, prior to vaccine availability, and a second
peak in September-November 2009, with low virus circulation
during the remainder of the winter [12]. Vaccination patterns in
study sites also mirrored national trends. CDC estimated state-
Table 1. Descriptive Characteristics of Enrolled Patients with Medically Attended Acute Respiratory Illness by Case Control Status.
Characteristics Influenza Positive Cases Influenza Negative Controls
N=1,011 % N=5,746 % P Value
Study community ,0.0011
Marshfield, WI 533 53% 2,388 42%
Rochester, NY 178 18% 259 5%
Southeast, MI 198 20% 1,086 19%
Nashville, TN 102 10% 2,013 35%
Age group ,0.0011
6 months–9 years 377 37% 1,791 31%
10–49 years 536 53% 2,193 38%
50+ years 98 10% 1,762 31%
Median (IQR) 6 13 28 6 29 54 ,0.0012
Sex 0.0861
Female 536 53% 3,216 56%
Male 475 47% 2,532 44%
Race3 ,0.0011
White 702 74% 4133 73%
Black 133 14% 1099 20%
Other 119 12% 394 7%
Insurance status ,0.0011
None 83 8% 290 5%
Private 720 71% 3,427 60%
Public only 208 21% 2,029 35%
Enrollment site ,0.0011
Outpatient Clinic 802 79% 3,326 58%
Emergency Room 117 12% 739 13%
Inpatient 92 9% 1,681 29%
High-risk condition ,0.0011
No 692 68% 3,126 54%
Yes 319 32% 2,620 46%
Onset to test ,0.0011
,3 days 632 63% 2,516 44%
3–6 days 338 33% 2,442 42%
7+ days 41 4% 788 14%
Vaccine (interval)
Pandemic (14 days) 15 1% 1042 18% ,0.0011
Pandemic (7 days) 22 2% 1107 19% ,0.0011
Seasonal (14 days) 203 20% 2182 38% ,0.0011
1Pearson test;
2Wilcoxon test;
3missing data for race (n = 177).
doi:10.1371/journal.pone.0023085.t001
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specific median vaccine coverage as of January 31, 2010 to be
23.9% (range 12.9% to 38.8%), consistent with our observations
[9].
One dose of pandemic vaccine was associated with an overall
effectiveness of 56%. For inactivated vaccines, estimated effec-
tiveness was 89% (95% CI, 15%–99%) among those aged 10–49
years, but significant effectiveness was not demonstrated in other
age groups. Relatively good vaccine effectiveness would be
expected in healthy young adults for the pandemic vaccine that
was well matched to the circulating strain. However, the wide
confidence interval suggests caution with interpretation of our
point estimate. Results from clinical trials conducted during
several recent seasons indicated that inactivated vaccines per-
formed better than live attenuated vaccines among healthy young
adults [13–15]. Lack of effectiveness of one dose of inactivated
vaccines in young children is not surprising, since two doses are
recommended and were often necessary for seroconversion [2,3].
We had insufficient power to adequately assess live attenuated
vaccine in adults or to compare vaccines. Use of a 7-day window
increased the number of vaccinated persons, increasing study
power. One dose of live attenuated pandemic vaccine was
estimated to be 82% effective in children aged 2 to 9 years, but
no effectiveness was demonstrated in those 10 to 49 in any
analysis. This finding also meets expectations, since live attenuated
vaccines have had high effectiveness in young children following
both one and two doses [16].
In contrast to Europe and Canada, the US opted not to use
adjuvanted vaccines for pandemic response. Such vaccines had
never been licensed in the United States and their use for
emergency response could have further delayed vaccination
efforts. In addition, immunogenicity of non-adjuvanted inactivated
vaccines was demonstrated in clinical trials [2,3]. Evaluation of
non-adjuvanted vaccines is important, since they may have fewer
local and systemic reactions, but can be less immunogenic in some
populations [17]. One dose of inactivated pandemic vaccine
resulted in hemagglutination inhibition (HI) titers $40 by 21 days
in .90% of study subjects aged 10 years or older; whereas two
doses were required to achieve this level in younger children
[2,18–21].
The only other large study of unadjuvanted vaccine was
conducted in Chinese school children, 78% of who were aged 12–
17 years. The reported effectiveness was 87% (95% CI, 75%–
93%). Methodologic concerns have been raised suggesting that this
study may have overestimated of effectiveness [22,23]. Nonethe-
less, the results are consistent with our results for inactivated US
vaccine among those aged 10–49 years. Other studies have
evaluated primarily adjuvanted pandemic vaccines. German and
Spanish studies reported very high effectiveness; however, neither
accounted for differences between vaccinated and unvaccinated
persons [24,25]. A small controlled Canadian study suggested that
one dose of adjuvanted vaccine was effective for young children
[26]. A study of 933 pandemic influenza cases and 1220 test
negative controls in England found overall effectiveness of 62%
(95% CI 33%–78%) for adjuvanted vaccine, with significant
effectiveness in children ,10 years (77%, 95% CI 11%–94%) and
those aged 10–24 years (100%, 80%–100%) [27]. Finally, a
multicenter study based on sentinel practitioner surveillance (918
cases and 1984 test-negative controls) in seven European countries
(80% adjuvanted vaccine) reported an adjusted vaccine effective-
ness of 72% (95% CI 46%–86%) [28].
Our study was limited by the few influenza illnesses after
pandemic vaccines became available, which diminished the power
overall and for subgroup analyses. Nonetheless, the consistency of
the findings in all statistical models, the finding of the most robust
effect in those 10 to 49 years with inactivated vaccines, the
effectiveness of live attenuated vaccine in young children in
secondary analyses, and the lack of effectiveness of seasonal
influenza vaccines, suggests that pandemic vaccines licensed for
use in the United States provided significant protection against
medically attended pandemic influenza illness.
Observational studies complement data from clinical trial data
to provide a more complete picture of influenza vaccine
effectiveness. Clinical trials for licensure of inactivated vaccines
Table 2. Descriptive Characteristics of Enrolled Patients with
Medically Attended Acute Respiratory Illness by Pandemic
Vaccine Status.
Characteristics Vaccinated Unvaccinated
N=1,057 % N=5,700 % P Value
Study community ,0.0011
Marshfield, WI 578 55% 2,343 41%
Rochester, NY 15 1% 422 7%
Southeast, MI 166 16% 1,118 20%
Nashville, TN 298 28% 1,817 32%
Age group ,0.0011
6 months–9 years 513 49% 1,655 29%
10–49 years 297 28% 2,433 43%
50+ years 247 23% 1,613 28%
Median (IQR) 2 11 47 7 27 52 ,0.0012
Sex 0.9961
Female 587 56% 3,165 56%
Male 470 44% 2,535 44%
Race3 ,0.0011
White 829 79% 4006 72%
Black 106 10% 1126 20%
Other 109 10% 404 7%
Insurance status ,0.0011
None 25 2% 348 6%
Private 677 64% 3,470 61%
Public only 355 34% 1,882 33%
Enrollment site ,0.0011
Outpatient 739 70% 3,389 59%
Emergency Dept 82 8% 774 14%
Inpatient 236 22% 1,537 27%
High-risk condition 0.6441
No 604 57% 3,214 56%
Yes 453 43% 2,486 44%
Symptom duration ,0.0011
,3 days 444 42% 2,704 47%
3–6 days 475 45% 2,305 40%
7+ days 138 13% 691 12%
Influenza test ,0.0011
Positive 15 1% 996 17%
Negative 1042 99% 4704 83%
1Pearson test;
2Wilcoxon test;
3missing data for race (n = 177).
doi:10.1371/journal.pone.0023085.t002
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rely in part on immunogenicity data which are not ideal predictors
of efficacy. Lack of randomization in observational studies
necessitates examination and control for factors that differ
systematically by both vaccination and case status. In our
population, age and timing of illness were the only factors strongly
associated with both vaccination and pandemic virus associated
illness. These as well as study community were accounted for in
both the primary and alternate models. Use of the test-positive
case vs. test-negative control methodology has the additional
advantage of controlling for difficult to measure factors associated
with both illness severity and the propensity to seek care when ill
[29,30].
Our results suggest that a single dose of a US licensed non-
adjuvanted pandemic vaccine was capable of preventing over
half of medical care visits associated with pandemic virus
infection, and that inactivated vaccines were very effective for
Table 3. Percent Vaccinated more than 14 Days Prior to Illness Onset by Case Control Status and Adjusted Vaccine Effectiveness,
by Age Group and Vaccine Type.
Age (Years) Influenza Positive Cases %Vaccinated
Influenza Negative Controls (N
Vaccinated/Total)
%Adjusted Vaccine Effectiveness1 (95%
Confidence Interval)
a. Any Pandemic Vaccine
All 1.5 (15/1011) 18.1 (1042/5746) 55.9 (22.7, 74.8)
0.5–9 1.6 (6/377) 28.3 (507/1791) 40.6 (251.7, 76.7)
10–49 0.9 (5/536) 13.2 (292/2193) 60.9 (20.5, 84.8)
$50 4.1 (4/98) 13.7 (243/1762) 25.8 (2230.5, 66.1)
b. Inactivated Pandemic Vaccine2
All 1.0 (10/999) 15.0 (826/5504) 61.7 (24.9, 80.5)
0.5–9 1.3 (5/373) 22.8 (376/1647) 31.6 (291.9, 75.6)
10–49 0. 2 (1/528) 9.9 (208/2096) 88.6 (15.2, 98.5)
$50 4.1 (4/98) 13.7 (242/1761) 25.9 (2230.9, 66.1)
c. Live Attenuated Pandemic Vaccine3
2–49 0.6 (5/860) 7.3 (214/2931) 39.9 (256.4, 76.9)
2–9 0.3 (1/330) 13.3 (130/977) 54.8 (2269.5, 94.5)
10–49 0.8 (4/530) 4.3 (84/1954) 21.0 (2196.5, 65.6)
1Adjusted for study community, cubic spline of age and time since 10/04/09 in days, insurance status, enrollment site, presence of high risk condition;
2Excludes all with live attenuated vaccination prior to illness onset;
3Excludes all with inactivated pandemic vaccination prior to illness onset and those not aged 2 to 49 years.
doi:10.1371/journal.pone.0023085.t003
Table 4. Percent Vaccinated more than 7 Days Prior to Illness Onset by Case Control Status and Adjusted Vaccine Effectiveness, by
Age Group and Vaccine Type.
Age (Years) Influenza Positive Cases %Vaccinated
Influenza Negative Controls (N
Vaccinated/Total)
%Adjusted Vaccine Effectiveness1 (95%
Confidence Interval)
a. Any Pandemic Vaccine
All 12.2 (22/1011) 19.3 (1107/5746) 57.9 (32.4, 73.7)
0.5–9 2.4 (9/377) 29.6 (531/1791) 50.8 (28.4, 77.7)
10–49 1.8 (9/536) 14.2 (312/2193) 59.0 (14.7, 80.3)
$50 4.1 (4/98) 15.0 (264/1762) 22.3 (2134.8, 74.3)
b. Inactivated Pandemic Vaccine2
All 1.0 (14/999) 15.9 (875/5504) 58.6 (26.2, 76.7)
0.5–9 1.3 (7/373) 23.7 (390/1647) 15.9 (2107.7, 66.0)
10–49 0. 2 (3/528) 10.6 (222/2096) 77.2 (24.8, 93.1)
$50 4.1 (4/98) 14.9 (263/1761) 22.2 (2135, 74.3)
c. Live Attenuated Pandemic Vaccine3
2–49 0.9 (8/860) 7.8 (230/2931) 60.6 (12.3, 82.3)
2–9 0.6 (2/330) 14.3 (140/977) 81.9 (13.6, 96.2)
10–49 1.1 (6/530) 4.6 (90/1954) 26.4 (291.3, 71.7)
1Adjusted for study community, cubic spline of age and time since 10/04/09 in days, insurance status, enrollment site, presence of high risk condition;
2Excludes all with live attenuated vaccination prior to illness onset;
3Excludes all with inactivated pandemic vaccination prior to illness onset and those not aged 2 to 49 years old.
doi:10.1371/journal.pone.0023085.t004
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those aged 10 to 49 years. Few children aged ,10 years received
2 doses, which limited effectiveness in this age group, and likely
decreased the overall effectiveness estimate, given the high
pandemic attack rate among young children. Despite significant
effectiveness, overall vaccine impact was limited by timing of its
availability.
Consistently conducted annual vaccine effectiveness will be
needed to assess the clinical effectiveness of new seasonal influenza
vaccines, which may be licensed for use in the US based on
enhanced immunogenicity alone (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm195483.htm). In order to
make vaccine- and age-specific estimates of vaccine effectiveness,
large annual studies should be a priority, given the universal US
recommendation for influenza vaccination.
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